KHPG(SZ:002773)2022-12-04 09:14Group 1: Company Strategy and Market Position - The company is developing post-medical insurance negotiation strategies and sales plans, emphasizing the competitive advantages of its product 康柏西普 (Conbercept) due to its proven efficacy and quality [4] - 康柏西普's global multi-center phase III clinical trials have commenced in over 30 countries with more than 300 research centers, with participant enrollment expected to complete by January 2020 [4][5] - The company plans to communicate with regulatory bodies like the U.S. FDA and European Medicines Agency regarding the clinical trial protocols for new indications [5] Group 2: Financial and Investment Updates - On November 8, 2019, the China Securities Regulatory Commission approved the company's application for a public offering of convertible bonds, pending formal approval [6] - The major shareholder plans to participate in the subscription of the convertible bonds [6] - As of November 29, 2019, the major shareholder, 鼎晖维鑫, has reduced its holdings to 15,275,400 shares, representing 1.7446% of the total shares [8] Group 3: Research and Development - The company has maintained a research and development expense ratio of around 12% in 2017 and 2018, with expectations for continued growth in R&D investment in the coming years [8] - The Beijing R&D center is crucial for the global development and commercialization of 康柏西普 and other products [6][7] Group 4: Product Development and Sales - The company has secured exclusive distribution rights for the IOPtiMate™ product in China, enhancing its ophthalmic product line [7] - The company aims for restorative growth in traditional Chinese medicine sales and to maintain growth in the chemical medicine sector in line with industry averages [8]